



✂ Author's Choice

# FADS3 is a $\Delta 14Z$ sphingoid base desaturase that contributes to gender differences in the human plasma sphingolipidome

Received for publication, November 14, 2019, and in revised form, December 16, 2019. Published, Papers in Press, December 20, 2019, DOI 10.1074/jbc.AC119.011883

Gergely Karsai<sup>‡</sup>, Museer Lone<sup>‡</sup>, Zoltán Kutalik<sup>§¶</sup>, J. Thomas Brenna<sup>||</sup>, Hongde Li<sup>\*\*</sup>, Duoja Pan<sup>\*\*</sup>, Arnold von Eckardstein<sup>‡</sup>, and Thorsten Hornemann<sup>‡1</sup>

From the <sup>‡</sup>Institute for Clinical Chemistry, University Hospital and University Zurich, 8091 Zürich, Switzerland, the <sup>§</sup>University Center for Primary Care and Public Health, University of Lausanne, 1010 Lausanne, Switzerland, the <sup>¶</sup>Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland, the <sup>||</sup>Dell Pediatric Research Institute, Departments of Chemistry, Pediatrics, and Nutrition, University of Texas, Austin, Texas 78723, and the <sup>\*\*</sup>Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas 75390

Edited by Dennis R. Voelker

Sphingolipids (SLs) are structurally diverse lipids that are defined by the presence of a long-chain base (LCB) backbone. Typically, LCBs contain a single  $\Delta 4E$  double bond (DB) (mostly d18:1), whereas the dienic LCB sphingadienine (d18:2) contains a second DB at the  $\Delta 14Z$  position. The enzyme introducing the  $\Delta 14Z$  DB is unknown. We analyzed the LCB plasma profile in a gender-, age-, and BMI-matched subgroup of the CoLaus cohort ( $n = 658$ ). Sphingadienine levels showed a significant association with gender, being on average  $\sim 30\%$  higher in females. A genome-wide association study (GWAS) revealed variants in the fatty acid desaturase 3 (*FADS3*) gene to be significantly associated with the plasma d18:2/d18:1 ratio ( $p = -\log 7.9$ ). Metabolic labeling assays, *FADS3* overexpression and knockdown approaches, and plasma LCB profiling in *FADS3*-deficient mice confirmed that *FADS3* is a *bona fide* LCB desaturase and required for the introduction of the  $\Delta 14Z$  double bond. Moreover, we showed that *FADS3* is required for the conversion of the atypical cytotoxic 1-deoxysphinganine (1-deoxySA, m18:0) to 1-deoxysphingosine (1-deoxySO, m18:1). HEK293 cells overexpressing *FADS3* were more resistant to m18:0 toxicity than WT cells. In summary, using a combination of metabolic profiling and GWAS, we identified *FADS3* to be essential for forming  $\Delta 14Z$  DB containing LCBs, such as d18:2 and m18:1. Our results unravel *FADS3* as a  $\Delta 14Z$  LCB desaturase, thereby disclosing the last missing enzyme of the SL *de novo* synthesis pathway.

Sphingolipids (SLs)<sup>2</sup> are a diverse class of lipids that share a long-chain base (LCB) backbone as a common structural ele-

ment. Forming an LCB is the first and rate-limiting reaction in the *de novo* synthesis of SL (Fig. S1). During SL synthesis, LCBs are usually *N*-acylated to a fatty acid (FA) of variable length ( $C_{16}$ – $C_{26}$ ) forming ceramides and conjugated to variable head-group structures forming complex SLs. LCBs are synthesized at the endoplasmic reticulum by the enzyme serine palmitoyltransferase. The most abundant LCB in mammals is the 18-carbon dihydroxy-amino-alkane sphingosine (d18:1) that is formed by the conjugation of L-serine with palmitoyl-CoA. Serine palmitoyltransferase, however, can metabolize a variety of other acyl-CoA in the range of  $C_{14}$ – $C_{18}$  and use alanine and glycine as alternative substrates. This forms a broad variety of LCBs, which differ by structure, function, and metabolism (1).

1-DeoxySLs are atypical SLs, which are generated from alanine instead of serine and involved in a variety of pathological conditions, including the rare hereditary sensory neuropathy type 1 (HSAN1) (2). Typically, LCBs present with a canonical  $\Delta 4E$  double bond (DB). However, the -dienic sphingoid base sphingadienine (d18:2) that is formed downstream of sphingosine (d18:1) has an additional DB at the  $\Delta 14Z$  position (3, 4). Recently, we reported that 1-deoxySO (m18:1) contains a  $\Delta 14Z$  DB but lacks the canonical DB at the  $\Delta 4E$  position (5). Whereas the  $\Delta 4E$  DB is introduced by the ceramide desaturase 1 (DEGS1), the enzyme responsible for the introduction of the  $\Delta 14Z$  DB is not known. Here, we identified fatty acid desaturase type 3 (*FADS3*) as a *bona fide* sphingoid base desaturase introducing a DB in the  $\Delta 14Z$  position and therefore responsible for converting d18:1 into d18:2 and 1-deoxySA (m18:0) into 1-deoxySO (m18:1).

## Results

Human plasma contains different SL classes, of which the most abundant are sphingomyelins (SM), hexosylceramides (HexCer), and ceramides (Cer). These classes are formed on a variety of LCB backbone structures, and variations in their LCB composition are associated with different pathological conditions (6–8). Differences in the LCB profile predict the risk for future diabetes type 2 (T2DM) independent from classical risk factors, such as BMI and blood glucose (9). Males and females

This work was supported by Swiss National Foundation (SNF) Grant 31003A/179371 and the Hurka and Swiss Life Foundation (to T.H.) and by the Novartis Foundation (to A.v.E.). The CoLaus study is supported by research grants from GlaxoSmith Kline, the Faculty of Biology and Medicine of Lausanne, and the Swiss National Science Foundation (Grants 33CS0-122661, 33CS0-139468, and 33CS0-148401). The authors declare that they have no conflicts of interest with the contents of this article.

✂ Author's Choice—Final version open access under the terms of the Creative Commons CC-BY license.

This article contains Figs. S1–S5.

<sup>1</sup> To whom correspondence should be addressed: Institute for Clinical Chemistry, University Hospital and University Zurich, 8091 Zürich, Switzerland. E-mail: thorsten.hornemann@usz.ch.

<sup>2</sup> The abbreviations used are: SL, sphingolipid; LCB, long-chain base; siFADS3, *FADS3* siRNA; siSCR, scrambled control siRNA; FA, fatty acid; DB,

double bond; SM, sphingomyelin(s); HexCer, hexosylceramide(s); Cer, ceramide(s); T2DM, diabetes type 2; BMI, body mass index; ER, endoplasmic reticulum; TPM, transcripts per million.

**Table 1**  
Baseline values of clinical parameters and long-chain base levels for each group (significant differences in bold)

Parameters	Female		Male		-Fold difference	-log(p)	
	Mean	S.D.	Mean	S.D.			
<i>n</i>	329		329				
Age	59.77	9.07	58.31	10.52	1.02	1.24	
BMI	28.61	5.03	27.82	4.28	1.03	1.50	
Waist/hip ratio	0.86	0.07	0.94	0.06	0.91	49.39	
Cholesterol (total)	5.94	1.09	5.63	0.94	1.06	4.08	
HDL	1.66	0.40	1.38	0.31	1.20	21.24	
LDL	3.59	0.95	3.51	0.82	1.02	0.66	
Trig	1.51	0.70	1.63	0.84	0.93	1.37	
Glu	6.02	1.67	6.14	1.79	0.98	0.43	
C <sub>16</sub> SO	<b>d16:1</b>	<b>19.63</b>	<b>5.73</b>	<b>16.58</b>	<b>5.21</b>	<b>1.18</b>	<b>11.58</b>
C <sub>16</sub> SA	<b>d16:0</b>	<b>0.51</b>	<b>0.20</b>	<b>0.44</b>	<b>0.18</b>	<b>1.14</b>	<b>4.65</b>
C <sub>17</sub> SO	<b>d17:1</b>	<b>9.52</b>	<b>2.63</b>	<b>7.91</b>	<b>2.28</b>	<b>1.20</b>	<b>15.45</b>
C <sub>18</sub> PhytoSO	t18:0	0.15	0.05	0.14	0.04	1.02	0.47
C <sub>18</sub> SO	<b>d18:1</b>	<b>97.23</b>	<b>19.15</b>	<b>88.32</b>	<b>16.54</b>	<b>1.10</b>	<b>9.45</b>
C <sub>18</sub> SA	<b>d18:0</b>	<b>3.51</b>	<b>1.08</b>	<b>3.12</b>	<b>1.00</b>	<b>1.12</b>	<b>5.48</b>
C <sub>18</sub> SAdienine	<b>d18:2</b>	<b>35.05</b>	<b>7.80</b>	<b>28.01</b>	<b>6.33</b>	<b>1.25</b>	<b>32.26</b>
C <sub>19</sub> SO	<b>d19:1</b>	<b>2.45</b>	<b>0.96</b>	<b>2.16</b>	<b>0.91</b>	<b>1.14</b>	<b>4.12</b>
C <sub>20</sub> SO	d20:1	0.20	0.06	0.19	0.05	1.03	0.57
C <sub>20</sub> SA	d20:0	0.02	0.01	0.02	0.01	1.02	0.28
1-DeoxySO	<b>m18:1</b>	<b>0.15</b>	<b>0.08</b>	<b>0.17</b>	<b>0.09</b>	<b>0.85</b>	<b>4.10</b>
1-DeoxySA	m18:0	0.08	0.04	0.09	0.04	0.95	0.85

have different risk profiles for T2DM. In men, T2DM is more frequently diagnosed at lower age and BMI, whereas obesity is more common in women. We therefore compared the LCB profile in an age- and BMI-matched subgroup of female and male participants of the CoLaus cohort ( $n = 329$  each). LDL cholesterol, triglycerides, and fasting glucose were not different between groups (Table 1), whereas total and HDL cholesterol were higher and waist/hip ratio was lower in females ( $p = -\log 49.4$ ). In plasma and tissue, the majority of LCBs is *N*-acylated and conjugated to variable headgroups. Nonconjugated LCBs in plasma are minor and less than 1% of the total. The combination of a variable LCB with a variable FA frequently results in the formation of isomeric structures (e.g. d18:1/24:0 versus d18:0/24:1), which interfere with the LCB analysis by LC-MS. To avoid interference with the *N*-acyl chain, we subjected the extracted lipids to a sequential acid/base hydrolysis (10) to remove the conjugated FA and headgroups. We therefore reported total LCB concentrations without considering previously conjugated *N*-acyl and headgroup structures.

The LCB profiling revealed d18:1 as the most abundant LCB in plasma (57%) followed by d18:2 (21%), d16:1 (5%), and d17:1 (4.2%). The remaining LCB species were less than 5% in total (Fig. 1A). Significant gender differences were seen for d18:2 ( $p = -\log 32.3$ ) followed by d17:1 ( $p = -\log 15.5$ ) and d16:1 ( $p = -\log 11.6$ ) LCBs (Fig. 1B). In average, d18:2 was about 30% higher in females, whereas its precursor d18:1 was only 10% increased. This indicates that the d18:1 to d18:2 conversion differs between genders. However, the enzyme responsible for this conversion was not known.


To identify the responsible  $\Delta 14Z$  desaturase, we used genome-wide SNP data, which were available for all European individuals of the cohort (11). As the enzyme converts d18:1 into d18:2, we hypothesized that genetic variations in the desaturase gene will be reflected by changes in the d18:1/d18:2 ratio. We therefore used this ratio as a metabolic outcome trait for a GWAS on 1100 participants of the CoLaus cohort for

whom the LCB profile was already available from an earlier study (9). The analysis revealed a group of adjacent SNPs, showing a significant association with the d18:1/d18:2 ratio. The strongest association was seen for SNP rs174455 ( $p = -\log 7.93$ ), which is located in an intronic region of the fatty acid desaturase 3 (FADS3) gene on chromosome 11q12.2–13.1 (Fig. 1D). The same region clusters two other desaturases, FADS1 and FADS2, which metabolize polyunsaturated fatty acids (12). In contrast, the function of FADS3 was still elusive. The FADS3 gene spans 17.9 kb of genomic DNA and has the same structure as FADS1 and FADS2, consisting of 12 exons and 11 introns. On the protein level, FADS3 is 52 and 62% homologous to FADS1 and FADS2, respectively.

To test whether FADS3 is a  $\Delta 14Z$  LCB desaturase, we expressed the mouse and human FADS3 cDNA in HEK293 cells. Endogenous d18:2 levels in HEK293 cells were low, indicating a low activity of the putative  $\Delta 14Z$  desaturase. For comparison, we also expressed the cDNA of mFADS1 and mFADS2. Expression levels were comparable for all constructs (Fig. 2A). Immune fluorescence microscopy showed an intracellular colocalization of FADS3 with calnexin, indicating that FADS3 is an ER protein (Fig. 2B).

Enzyme activity was tested in human and mouse FADS3-expressing cells supplemented either with isotope-labeled (d7)d18:0 or (d3)m18:0. The free LCBs were absorbed by the cells (13) and metabolized to (d7)ceramide and downstream products, such as (d7)SM and (d7)HexCer (Fig. S2A). After 48 h, the lipids were extracted and hydrolyzed, and the LCB profile were analyzed by LC-MS. In both mFADS3- and hFADS3-expressing cells, we observed a strong increase in d18:2 (Fig. 2C and Fig. S2B), which was not seen in mFADS1- or mFADS2-expressing cells. In addition, FADS3-expressing cells showed an increased conversion of m18:0 into m18:1, indicating that the  $\Delta 14Z$  DB in 1-deoxySO is also formed by FADS3 (Fig. 2D and Fig. S2C). To test whether FADS3 acts on *N*-acylated or free LCBs, we treated cells with fumonisin B1 (FB1). FB1 inhibits ceramide synthase and therefore the *N*-acylation of LCBs. In the presence of FB1, the conversion was about 70% reduced, but a significant amount of (d7)d18:1 was still converted into (d7)d18:2. This was confirmed *in vitro*, by adding either the free LCB (d7)d18:1 or the *N*-acylated d18:1/6:0 to cell-free extract of FADS3-expressing HEK cells. Both the free and the *N*-acylated LCBs were effectively converted into their dienic forms (Fig. 2F), indicating that FADS3 is capable of metabolizing both free and *N*-acylated LCBs.

For further confirmation, we performed the reverse experiments by knocking down endogenous FADS3 in HeLa cells, which had a higher endogenous FADS3 expression than HEK293 cells. Transfection with FADS3 siRNA (siFADS3) abolished FADS3 expression almost completely compared with cells transfected with control siRNA (siSCR) (Fig. 3A). LCB profiling revealed that almost no isotope-labeled (d7)d18:2 was formed in the absence of FADS3, whereas in siSCR-treated cells, a significant conversion of (d7)d18:0 into (d7)d18:1 and finally into (d7)d18:2 was observed (Fig. 3B). Similarly, the conversion of isotope-labeled (d3)m18:0 into (d3)m18:1 was mostly abolished in siFADS3-treated cells (Fig. 3C and Fig. S4).



**Figure 1. LCB profiling and genetic associations.** *A* and *B*, long-chain base profile in human plasma. *A*, relative distribution of the most abundant LCBs in human plasma. *B*, differences in the concentration of the major plasma LCBs between females (F) and males (M). *C*, relative distribution of the LCB species d18:0, d18:1, and d18:2 in Cer, HexCer, and SM in human plasma. The LCBs reflect the sum of Cer ( $C_{16:0}$ ,  $C_{18:0}$ ,  $C_{20:0}$ ,  $C_{22:0}$ ,  $C_{24:0}$ , and  $C_{24:1}$ ), SM ( $C_{16:0}$ ,  $C_{18:0}$ ,  $C_{20:0}$ ,  $C_{22:0}$ ,  $C_{24:0}$ , and  $C_{24:1}$ ), and HexCer ( $C_{16:0}$ ,  $C_{22:0}$ ,  $C_{24:0}$ , and  $C_{24:1}$ ). *D*, Manhattan plot of the GWAS revealed SNP rs174455 on Chromosome 11 to be significantly associated with the d18:1/d18:2 ratio ( $p = -\log 7.93$ ). Error bars, S.D.

Finally, we analyzed the LCB profile in plasma of FADS3-deficient mice (14). No d18:2 was detected in plasma of FADS<sup>-/-</sup> mice, whereas FADS<sup>+/-</sup> mice had about 50% of the WT levels (Fig. 3D).

To see whether the  $\Delta 14Z$  DB has biological relevance, we cultured WT and FADS3-overexpressing cells with increasing amounts of m18:0 and quantified the number of surviving cells after 48 h. HEK293 cells overexpressing FADS3 were significantly more resistant to m18:0 toxicity than WT cells (Fig. 3E).

As d18:2 plasma levels were higher in females, we compared the FADS3 tissue expression between males and females using the public gene expression data from the GTEx portal ([\[gtexportal.org\]\(https://gtexportal.org\)\).<sup>3</sup> Overall, the highest FADS3 expression was seen for peripheral nerve, aorta, and adipose tissue. The majority of tissues showed higher FADS3 expression in females. The most pronounced difference was seen for adipose tissues, with 194.6 transcripts per million \(TPM\) in females versus 166.7 TPM in males.](https://</a></p>
</div>
<div data-bbox=)


## Discussion

Sphingadienine (d18:2) is an atypical sphingoid base that contains two DBs, a  $\Delta 4E$  and a  $\Delta 14Z$  (3, 15). Whereas the  $\Delta 4E$

<sup>3</sup> Please note that the JBC is not responsible for the long-term archiving and maintenance of this site or any other third party hosted site.



**ACCELERATED COMMUNICATION:**  $\Delta 14Z$  sphingoid base desaturase FADS3



DB is introduced by DEGS1 during SL *de novo* synthesis, the enzyme introducing the  $\Delta 14Z$  DB was not known. However, in a gender-, age-, and BMI-matched cohort, we identified d18:2 as the second most abundant LCB (Fig. 1A) and significantly higher in females than in males. This confirms data from two recent epidemiologic studies, which also report gender-specific difference in d18:2-based SLs (16, 17).

Although, d18:2 was first described in the late 1960s (3), the responsible enzyme forming the  $\Delta 14Z$  double was not known. Based on genetic association studies in combination with *in vivo* and *in vitro* experiments, we identified FADS3 as a *bona fide*  $\Delta 14Z$  long-chain base desaturase. Data from the GTEx database revealed generally higher FADS3 expression in females for many tissues, including peripheral nerve and adipose tissue, but also liver, kidney, and muscle. Higher FADS3 expression was also reported for female mice (18) and might explain the gender-specific differences in d18:2 plasma levels.

Although human FADS3 was first cloned in 2000 (19), its function remained elusive. FADS3 is composed of an N-terminal cytochrome  $b_5$ -like domain and three histidine motifs at the C-terminal ends, which is characteristic for membrane-bound front end desaturases (20). *In vitro* studies indicated that FADS3 is specific for *trans*-vaccenic acid (*trans*-11–18:1), catalyzing the synthesis of a *trans*-11,*cis*-13-linoleic acid isomer ( $\Delta 13$  desaturation) (21). Interestingly, an earlier GWAS on genetic determinants of circulating sphingolipids found FADS3 to be strongly associated with SM species containing monounsaturated *N*-acyl chains (22). As d18:1-based SLs with unsaturated acyl chains (e.g. SM d18:1/24:1) are isobaric to SLs with saturated fatty acids formed on a d18:2 backbone (e.g. SM d18:2/24:0), these associations could also refer to -dienic SM species (Figs. S3 and S5).

FADS3 localizes to human chromosome 11q13 (23), which is known as a cancer hotspot locus (19, 24). It is located in a gene cluster together with FADS1 and FADS2, which were identified previously as  $\Delta$ -5 and  $\Delta$ -6 desaturases. FADS3 mRNA expression responds inversely to FADS1 and FADS2 expression levels. In FADS2-deficient mice, FADS3 expression increased 3-fold (25), and reducing FADS1 and FADS2 expression by docosahexaenoic acid and arachidonic acid increases expression of FADS3 (26). FADS3 is spliced, yielding to alternative transcripts, which are conserved in several mammalian and avian species (18, 27). However, it is not yet clear whether these alternative transcripts are catalytically active.

Little is known about the function of d18:2-based SLs. Previously, plasma levels of d18:2 SLs were inversely associated with the incidence of cardiovascular events (8), the body mass index, and the HOMA (homeostatic model assessment) index (16). It serves as a backbone for complex sphingolipids (Fig. 1C) and forms -dienic LCB phosphates (SAdienine-1P) (29). Free SAdienes and synthetic analogues exhibit cytotoxic and anti-

proliferative effects in cancer and noncancer cells (30, 31) and were associated with the inhibition of colon tumorigenesis in mouse models (32, 33). Mitochondrial and cellular pools of d18:2-based ceramides were elevated in embryonic fibroblasts derived from double-knockout BAX-BAK mice and a mouse-derived immortalized iBMK cell line (34). It is noteworthy that the  $\Delta 14$  DB in d18:2 is in *cis* conformation, introducing a kink into the otherwise straight LCB structure. This might affect the lateral assembly of d18:2-based SLs in biological membranes and could interfere with membrane nanodomain formation and receptor clustering. In the first reports, FADS3 KO mice showed no overt phenotype (14). No significant differences in survival, fertility, or growth rate were seen. However, FADS3 KO mice were not yet tested under challenged metabolic conditions, such as high-fat diet. Genetic variants of FADS3 are associated with familial combined hyperlipidemia in the Mexican population (35), and the FADS3 SNP rs174455 was negatively associated with docosahexaenoic acid levels in red blood cell phospholipids (36).

1-DeoxySLs are an atypical class of toxic sphingolipids associated with the rare inherited neuropathy HSAN1 (37) and macular telangiectasia type 2 (38). In contrast to canonical LCBs, m18:1 contains only a single DB in  $\Delta 14Z$  position but lacks the  $\Delta 4E$  DB (5). Here we showed that FADS3 is also responsible for the conversion of m18:0 into m18:1 (Figs. 2D and 3C and Figs. S2 and S4). In addition, we showed that FADS3-expressing cells were more resistant to m18:0 toxicity than WT cells (Fig. 3E). This supports recent reports indicating that m18:0 based 1-deoxySL species are more associated with toxic effects than their unsaturated forms (39). In that respect, FADS3 might contribute to a physiological detoxification of 1-deoxySLs.


It is not fully clear yet whether FADS3 activity is specific for *N*-acylated LCBs or whether it can also metabolize the free form. After blocking *N*-acylation with FB1, we still observed a conversion of (d7)d18:1 into (d7)d18:2, albeit at reduced levels (Fig. 2E). Also *in vitro* assays showed that FADS3 (Fig. 2F) is capable in converting both the *N*-acylated and the free LCB. However, as free LCBs are typically minor, the conversion of free LCBs is likely of limited biological relevance.

We recently reported that DEGS1 deficiency causes leukodystrophy and peripheral hypomyelination, which was associated with a pathologically increased formation of saturated dihydroSL species (13) and the formation of an atypical mono-unsaturated d18:1 isomer. Further analysis showed that this isomer contained a  $\Delta 14Z$  DB but lacked the canonical  $\Delta 4E$  DB. This suggests that FADS3 can also metabolize saturated d18:0, although the atypical d18:1 ( $\Delta 14Z$ ) isomer was only detected under conditions with reduced DEGS1 activity.

In conclusion, we identified FADS3 as a  $\Delta 14Z$  LCB desaturase introducing a  $\Delta 14Z$  DB into d18:1- and m18:0-based SLs and likely also other LCB substrates. This illuminates the last obscure step in

**Figure 2. FADS3 mediates the  $\Delta 14$  LCB desaturation in mammalian cells.** A, Western blotting of HEK293 cells stably expressing mFADS1–3 (Myc-DDK) and hFADS1–3 (V5). B, intracellular localization of hFADS3-V5 (red) overlaps with the ER marker calnexin (green). Scale bar, 10  $\mu$ m. Insets, 3-fold magnification. Scale bar, 5  $\mu$ m. C, cells stably expressing mFADS1–3 and hFADS3 cultured for 48 h with isotope-labeled (d7)d18:0. The levels of (d7)d18:2 were significantly elevated in mFADS3- and hFADS3-overexpressing cells but not altered in mFADS1 and mFADS2 cells. D, FADS1–3-expressing HEK293 cells supplemented with isotope-labeled (d3)m18:0 for 48 h. (d3)m18:1 levels were higher in FADS3-expressing cells compared with WT, mFADS1, and mFADS2 cells. E, HEK293 cells supplemented with (d7)d18:1 in the presence or absence of FB1 (35  $\mu$ M). (d7)d18:2 formation was reduced but still detectable in the presence of FB1, indicating that FADS3 can also metabolize the free LCB. F, FADS3 *in vitro* activity with the free LCB (d7) d18:1 and the *N*-acylated form (d18:1/6:0). The free and the *N*-acylated form were both rapidly converted into (d7)d18:2 and d18:2/6:0, respectively. Data are shown as mean  $\pm$  S.D. (error bars),  $n = 3$ , paired *t* test; \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ ; n.s., not significant.

**ACCELERATED COMMUNICATION:  $\Delta 14Z$  sphingoid base desaturase FADS3**



**Figure 3. FADS3 is required for  $\Delta 14Z$  LCB desaturation.** *A*, HeLa cells transfected with siFADS3 or siSCR. The silencing of hFADS3 was confirmed by Western blotting with a polyclonal antibody against FADS3. Calnexin was used as a loading control ( $n = 3$ ). *B–D*, sphingoid base profiling of cells and plasma. *B*, HeLa cells were transfected with siSCR and siFADS3 for 72 h and subsequently cultured for 24 h in the presence of  $2 \mu\text{M}$  (d7)d18:0 and (d3)m18:0. The formation of (d7)d18:2 was significantly decreased in the siFADS3-treated cells. No difference was seen for the precursors (d7)d18:0 and (d7)d18:1. *C*, the conversion of (d3)m18:0 into (d3)m18:1 was also reduced in siFADS3-treated cells compared with controls (siSCR). Data are shown as mean  $\pm$  S.D. (error bars), unpaired *t* test; \*,  $p < 0.05$ ; \*\*\*,  $p < 0.001$ . *D*, d18:2 was absent in plasma of the two FADS3(–/–) mice (M1/M2), and about 50% in the FADS3(+/-) mice compared with WT. Total d18:1 levels were not different. *E*, WT and FADS3-overexpressing HEK293 cells were plated at low density (150,000 cells/well of a 24-well plate) and supplemented with increasing concentrations of m18:0 (0–1.5  $\mu\text{M}$ ). After 48 h, the number of attached cells was significantly higher in FADS3-overexpressing cells than in WT. Data are shown as mean  $\pm$  S.D. ( $n = 3$ ) and compared by two-way analysis of variance with Bonferroni's correction \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; n.s., not significant. *F*, interplay between the two LCB desaturases DEGS1 and FADS3. DEGS1 introduces the  $\Delta 4E$  DB into d18:0, forming d18:1, whereas FADS3 introduces the  $\Delta 14Z$  DB into d18:1 and m18:0.

the SL *de novo* synthesis pathways, as the enzyme that forms d18:2 was not yet identified. The activity of FADS3 seems to be higher in females and relates to gender-specific differences in the plasma sphingolipidome. In addition, we propose that FADS3 could be involved in the detoxification of 1-deoxySLs. However, further studies are required to understand the role of FADS3 under physiological and pathophysiological conditions.

**Experimental procedures**

**Approvals**

The Colaus study was conducted according to the principles expressed in the Declaration of Helsinki and approved by the Institutional Ethics Committee of the University of Lausanne.

Animal studies were approved by the Cornell University Institutional Animal Care and Use Committee (IACUC protocol 2011-0007).

### Human samples and genome-wide association scan

Two subgroups of age- and BMI-matched females and males ( $n = 329$  each) were selected from the CoLaus cohort (9, 40). Genotyping and imputation of the cohort was described previously (41). Briefly, individuals with genotyping inconsistencies or with genotyping efficiency below 90% were removed. SNPs with genotyping efficiency below 70% or with Hardy–Weinberg  $p$  values smaller than  $1E-7$  were removed. Duplicate individuals and first and second degree relatives were identified by computing genomic identity-by-descent coefficients, using PLINK (42). Imputation was performed using the method of Marchini *et al.* (43), using IMPUTE version 0.2.0, CEU haplotypes, and the fine scale recombination map from HapMap release 21. Given the non-Gaussian distribution of the examined LCBs, inverse normal quantile transformation was applied, regressing out age, sex, and the first four ancestry principal components. The residual trait has been rescaled to have zero mean and unit variance. Linear regression analysis has been performed for 2,557,249 imputed genetic markers as explanatory variables. The probabilistic genotypes were converted to allele dosages.

### Cells and cell culture

HEK293 and HeLa cells (American Type Culture Collection) were cultured in Dulbecco's modified Eagle's medium (Thermo Fisher Scientific) with 10% fetal bovine serum and 1% penicillin/streptomycin (37 °C in 5% CO<sub>2</sub>). Transfection was done using Lipofectamine 3000 (Thermo Fisher Scientific). Transfected cells were cultured under Blasticidin (Thermo Fisher Scientific) for selection. hFADS3 and control siRNA was obtained from Origene and transfected with RNAiMAX (Thermo Fisher Scientific) according to the manufacturer's protocol.

### Immunohistochemistry

HeLa cells were transfected and grown for 24 h on 15-mm coverslips, fixed in 4% paraformaldehyde (30 min, room temperature), and washed in PBS. Cells were blocked for 2 h in PBS, 5% BSA, 1% normal goat serum, and 0.25% Triton X-100) and incubated with the primary antibodies overnight, and anti-calnexin antibody (Sigma, C4731) and anti-V5 antibody (Bio-Rad MCA1360) were used. Secondary antibodies (1:2000, Invitrogen) and 4',6-diamidino-2-phenylindole (Invitrogen) was added for 4 h. Cells were mounted on glass slides with ProLong Diamond Antifade Mountant (Thermo Fisher Scientific). Pictures were acquired on a confocal laser-scanning microscope (Leica SP8, Leica Microsystems, Wetzlar, Germany, HC PL APO CS2  $\times 63$  numeric aperture, 1.4 oil) at 90.4 nm  $\times$  90.4 nm  $\times$  300 nm ( $x \times y \times z$ ) resolution and analyzed using the Fiji image-processing package (44).

### Protein detection

Protein isolation and Western blotting were carried out as described elsewhere (13).

### Cloning

FADS1 (NM\_013402.4), FADS2 (NM\_004265.3), and FADS3 (XM\_011545023.2) were amplified from a commercially available cDNA library using the following primers: FADS1 Forward, caccatgggaacgcgcgctgcgagg; FADS1 Reverse, ttggtgaagataggcatctagcag; FADS2 Forward, caccatggggaaggagggaaccag; FADS2 Reverse, ttggtgaagtaggcgtccag; FADS3 Forward, caccatggggcgctcggggagcc; FADS3 Reverse, ctgatggagtaggcgtccagatg.

The PCR product was cloned into the pcDNA3.1 V5-His-TOPO vector (Thermo Fisher Scientific) and verified using Sanger sequencing. Myc-DDK-tagged mouse FADS1–3 plasmids were commercially available (Origene).

### Lipidomics analysis

Lipidomics analysis was performed as described previously (13, 28) using the internal standards (100 pmol/ml, Avanti Polar Lipids): (d5) 1-desoxymethylsphinganine (m17:0), dihydroceramide (d18:0/12:0), ceramide (d18:1/12:0), 1-deoxydihydroceramide (m18:0/12:0), 1-deoxyceramide (m18:1/12:0), glucosylceramide (d18:1/8:0), and sphingomyelin (d18:1/12:0).

The plasma LCB profile was analyzed as described previously (10). For quantification, (d5) 1-desoxymethylsphinganine (m17:0) was used as an internal standard (Avanti Polar Lipids).

### Metabolic labeling assay

250,000 Cells were seeded and cultured in 6-well plates to 70–80% confluence. New medium containing isotope-labeled (d3)m18:0, (d7)d18:0, or (d7)d18:1 (Avanti Polar Lipids) was added. After 24 or 48 h, cells were harvested, counted (Beckman Coulter Vi-Cell XR), pelleted (600  $\times g$  at 4 °C), and stored at  $-20$  °C.

### Activity assay

FADS3 cells were lysed by sonication, and the homogenate was centrifuged at 13,000  $\times g$  for 5 min. For each condition, 100  $\mu g$  of lysate in 100  $\mu l$  of PBS + 1 mM NAD<sup>+</sup> were incubated with 500 pmol of (d7)d18:1 or d18:1/6:0 for 5 min. The products were measured by LC-MS.

### Statistical analysis

Statistical analysis was performed using GraphPad Prism 8. A  $p$  value of  $<0.05$  was considered statistically significant.

---

*Author contributions*—G. K., A. v. E., and T. H. conceptualization; G. K., A. v. E., and T. H. data curation; G. K., A. v. E., and T. H. formal analysis; G. K., Z. K., A. v. E., and T. H. supervision; G. K., Z. K., and T. H. validation; G. K., M. A. L., Z. K., J. T. B., H. L., D. P., A. v. E., and T. H. investigation; G. K., Z. K., and T. H. visualization; G. K. and Z. K. methodology; G. K., Z. K., A. v. E., and T. H. writing—original draft; G. K., Z. K., J. T. B., H. L., A. v. E., and T. H. writing—review and editing; Z. K., J. T. B., H. L., D. P., A. v. E., and T. H. resources; A. v. E. and T. H. funding acquisition; A. v. E. and T. H. project administration.

---

*Acknowledgments*—We thank Peter Vollenweider (CHUV, Lausanne) for his contribution and help with the CoLaus samples as well as Yu Wei for practical help in the laboratory.

---



## References

- Carreira, A. C., Santos, T. C., Lone, M. A., Zupančič, E., Lloyd-Evans, E., de Almeida, R. F. M., Hornemann, T., and Silva, L. C. (2019) Mammalian sphingoid bases: biophysical, physiological and pathological properties. *Prog. Lipid Res.* **75**, 100988 [CrossRef Medline](#)
- Lone, M. A., Santos, T., Alecu, I., Silva, L. C., and Hornemann, T. (2019) 1-Deoxysphingolipids. *Biochim. Biophys. Acta Mol. Cell. Biol. Lipids* **1864**, 512–521 [CrossRef Medline](#)
- Renkonen, O., and Hirvisalo, E. L. (1969) Structure of plasma sphingadine. *J. Lipid Res.* **10**, 687–693 [Medline](#)
- Renkonen, O. (1970) Presence of sphingadine and *trans*-monoenoic fatty acids in ceramide monoheptosides of human plasma. *Biochim. Biophys. Acta* **210**, 190–192 [CrossRef Medline](#)
- Steiner, R., Saied, E. M., Othman, A., Arenz, C., Maccarone, A. T., Poad, B. L., Blanksby, S. J., von Eckardstein, A., and Hornemann, T. (2016) Elucidating the chemical structure of native 1-deoxysphingosine. *J. Lipid Res.* **57**, 1194–1203 [CrossRef Medline](#)
- Othman, A., Rützi, M. F., Ernst, D., Saely, C. H., Rein, P., Drexel, H., Porretta-Serapiglia, C., Lauria, G., Bianchi, R., von Eckardstein, A., and Hornemann, T. (2012) Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome? *Diabetologia* **55**, 421–431 [CrossRef Medline](#)
- Othman, A., Saely, C. H., Muendlein, A., Vonbank, A., Drexel, H., von Eckardstein, A., and Hornemann, T. (2015) Plasma 1-deoxysphingolipids are predictive biomarkers for type 2 diabetes mellitus. *BMJ Open Diabetes Res. Care* **3**, e000073 [CrossRef Medline](#)
- Othman, A., Saely, C. H., Muendlein, A., Vonbank, A., Drexel, H., von Eckardstein, A., and Hornemann, T. (2015) Plasma C20-sphingolipids predict cardiovascular events independently from conventional cardiovascular risk factors in patients undergoing coronary angiography. *Atherosclerosis* **240**, 216–221 [CrossRef Medline](#)
- Mwinyi, J., Boström, A., Fehrer, I., Othman, A., Waeber, G., Marti-Soler, H., Vollenweider, P., Marques-Vidal, P., Schiöth, H. B., von Eckardstein, A., and Hornemann, T. (2017) Plasma 1-deoxysphingolipids are early predictors of incident type 2 diabetes mellitus. *PLoS One* **12**, e0175776 [CrossRef Medline](#)
- Alecu, I., Othman, A., Penno, A., Saied, E. M., Arenz, C., von Eckardstein, A., and Hornemann, T. (2017) Cytotoxic 1-deoxysphingolipids are metabolized by a cytochrome P450-dependent pathway. *J. Lipid Res.* **58**, 60–71 [CrossRef Medline](#)
- Antiochos, P., Marques-Vidal, P., McDaid, A., Waeber, G., and Vollenweider, P. (2016) Association between parental history and genetic risk scores for coronary heart disease prediction: the population-based CoLaus study. *Atherosclerosis* **244**, 59–65 [CrossRef Medline](#)
- Park, H. G., Park, W. J., Kothapalli, K. S., and Brenna, J. T. (2015) The fatty acid desaturase 2 (FADS2) gene product catalyzes  $\Delta 4$  desaturation to yield *n*-3 docosahexaenoic acid and *n*-6 docosapentaenoic acid in human cells. *FASEB J.* **29**, 3911–3919 [CrossRef Medline](#)
- Karsai, G., Kraft, F., Haag, N., Korenke, G. C., Hänisch, B., Othman, A., Suriyanarayanan, S., Steiner, R., Knopp, C., Mull, M., Bergmann, M., Schröder, J. M., Weis, J., Elbracht, M., Begemann, M., et al. (2019) DEGS1-associated aberrant sphingolipid metabolism impairs nervous system function in humans. *J. Clin. Invest.* **129**, 1229–1239 [CrossRef Medline](#)
- Zhang, J. Y., Qin, X., Liang, A., Kim, E., Lawrence, P., Park, W. J., Kothapalli, K. S. D., and Brenna, J. T. (2017) Fads3 modulates docosahexaenoic acid in liver and brain. *Prostaglandins Leukot. Essent. Fatty Acids* **123**, 25–32 [CrossRef Medline](#)
- Ryan, E., Nguyen, C. Q. N., Shiea, C., and Reid, G. E. (2017) Detailed structural characterization of sphingolipids via 193 nm ultraviolet photodissociation and ultra high resolution tandem mass spectrometry. *J. Am. Soc. Mass Spectrom.* **28**, 1406–1419 [CrossRef Medline](#)
- Chew, W. S., Torta, F., Ji, S., Choi, H., Begum, H., Sim, X., Khoo, C. M., Khoo, E. Y. H., Ong, W. Y., Van Dam, R. M., Wenk, M. R., Tai, E. S., and Herr, D. R. (2019) Large-scale lipidomics identifies associations between plasma sphingolipids and T2DM incidence. *JCI Insight* **5**, 126925 [CrossRef Medline](#)
- Huynh, K., Barlow, C. K., Jayawardana, K. S., Weir, J. M., Mellett, N. A., Cinel, M., Magliano, D. J., Shaw, J. E., Drew, B. G., and Meikle, P. J. (2019) High-throughput plasma lipidomics: detailed mapping of the associations with cardiometabolic risk factors. *Cell Chem. Biol.* **26**, 71–84.e4 [CrossRef Medline](#)
- Pédrone, F., Blanchard, H., Kloareg, M., D'andréa, S., Daval, S., Rioux, V., and Legrand, P. (2010) The fatty acid desaturase 3 gene encodes for different FADS3 protein isoforms in mammalian tissues. *J. Lipid Res.* **51**, 472–479 [CrossRef Medline](#)
- Marquardt, A., Stöhr, H., White, K., and Weber, B. H. (2000) cDNA cloning, genomic structure, and chromosomal localization of three members of the human fatty acid desaturase family. *Genomics* **66**, 175–183 [CrossRef Medline](#)
- Park, W. J., Kothapalli, K. S., Reardon, H. T., Kim, L. Y., and Brenna, J. T. (2009) Novel fatty acid desaturase 3 (FADS3) transcripts generated by alternative splicing. *Gene* **446**, 28–34 [CrossRef Medline](#)
- Rioux, V., Pédrone, F., Blanchard, H., Duby, C., Boulrier-Monthéan, N., Bernard, L., Beauchamp, E., Catheline, D., and Legrand, P. (2013) Transvaccenate is  $\Delta 13$ -desaturated by FADS3 in rodents. *J. Lipid Res.* **54**, 3438–3452 [CrossRef Medline](#)
- Hicks, A. A., Pramstaller, P. P., Johansson, A., Vitart, V., Rudan, I., Ugocsai, P., Aulchenko, Y., Franklin, C. S., Liebisch, G., Erdmann, J., Jonasson, I., Zorkoltseva, I. V., Pattaro, C., Hayward, C., Isaacs, A., et al. (2009) Genetic determinants of circulating sphingolipid concentrations in European populations. *PLoS Genet.* **5**, e1000672 [CrossRef Medline](#)
- Blanchard, H., Legrand, P., and Pédrone, F. (2011) Fatty acid desaturase 3 (Fads3) is a singular member of the Fads cluster. *Biochimie* **93**, 87–90 [CrossRef Medline](#)
- Park, W. J., Kothapalli, K. S., Lawrence, P., and Brenna, J. T. (2011) FADS2 function loss at the cancer hotspot 11q13 locus diverts lipid signaling precursor synthesis to unusual eicosanoid fatty acids. *PLoS One* **6**, e28186 [CrossRef Medline](#)
- Stroud, C. K., Nara, T. Y., Roqueta-Rivera, M., Radlowski, E. C., Lawrence, P., Zhang, Y., Cho, B. H., Segre, M., Hess, R. A., Brenna, J. T., Haschek, W. M., and Nakamura, M. T. (2009) Disruption of FADS2 gene in mice impairs male reproduction and causes dermal and intestinal ulceration. *J. Lipid Res.* **50**, 1870–1880 [CrossRef Medline](#)
- Reardon, H. T., Hsieh, A. T., Park, W. J., Kothapalli, K. S., Anthony, J. C., Nathanielsz, P. W., and Brenna, J. T. (2013) Dietary long-chain polyunsaturated fatty acids upregulate expression of FADS3 transcripts. *Prostaglandins Leukot. Essent. Fatty Acids* **88**, 15–19 [CrossRef Medline](#)
- Brenna, J. T., Kothapalli, K. S., and Park, W. J. (2010) Alternative transcripts of fatty acid desaturase (FADS) genes. *Prostaglandins Leukot. Essent. Fatty Acids* **82**, 281–285 [CrossRef Medline](#)
- Chew, W. S., Torta, F., Ji, S., Choi, H., Begum, H., Sim, X., Khoo, C. M., Khoo, E. Y. H., Ong, W. Y., Van Dam, R. M., Wenk, M. R., Tai, E. S., and Herr, D. R. (2019) Large-scale lipidomics identifies associations between plasma sphingolipids and T2DM incidence. *JCI Insight* **5**, 126925 [CrossRef Medline](#)
- Sutter, I., Velagapudi, S., Othman, A., Riwanto, M., Manz, J., Rohrer, L., Rentsch, K., Hornemann, T., Landmesser, U., and von Eckardstein, A. (2015) Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-apoptotic activity of HDL. *Atherosclerosis* **241**, 539–546 [CrossRef Medline](#)
- Sugawara, T., Zaima, N., Yamamoto, A., Sakai, S., Noguchi, R., and Hirata, T. (2006) Isolation of sphingoid bases of sea cucumber cerebroside and their cytotoxicity against human colon cancer cells. *Biosci. Biotechnol. Biochem.* **70**, 2906–2912 [CrossRef Medline](#)
- Struckhoff, A. P., Bittman, R., Burow, M. E., Clejan, S., Elliott, S., Hammond, T., Tang, Y., and Beckman, B. S. (2004) Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. *J. Pharmacol. Exp. Ther.* **309**, 523–532 [CrossRef Medline](#)
- Symolon, H., Schmelz, E. M., Dillehay, D. L., and Merrill, A. H., Jr. (2004) Dietary soy sphingolipids suppress tumorigenesis and gene expression in 1,2-dimethylhydrazine-treated CF1 mice and ApcMin/+ mice. *J. Nutr.* **134**, 1157–1161 [CrossRef Medline](#)
- Fyrst, H., Oskouiian, B., Bandhuvula, P., Gong, Y., Byun, H. S., Bittman, R., Lee, A. R., and Saba, J. D. (2009) Natural sphingadienes inhibit Akt-dependent signaling and prevent intestinal tumorigenesis. *Cancer Res.* **69**, 9457–9464 [CrossRef Medline](#)



34. Zhang, T., Barclay, L., Walensky, L. D., and Saghatelian, A. (2015) Regulation of mitochondrial ceramide distribution by members of the BCL-2 family. *J. Lipid Res.* **56**, 1501–1510 [CrossRef Medline](#)
35. Plaisier, C. L., Horvath, S., Huertas-Vazquez, A., Cruz-Bautista, I., Herrera, M. F., Tusie-Luna, T., Aguilar-Salinas, C., and Pajukanta, P. (2009) A systems genetics approach implicates USF1, FADS3, and other causal candidate genes for familial combined hyperlipidemia. *PLoS Genet.* **5**, e1000642 [CrossRef Medline](#)
36. Koletzko, B., Lattka, E., Zeilinger, S., Illig, T., and Steer, C. (2011) Genetic variants of the fatty acid desaturase gene cluster predict amounts of red blood cell docosahexaenoic and other polyunsaturated fatty acids in pregnant women: findings from the Avon Longitudinal Study of Parents and Children. *Am. J. Clin. Nutr.* **93**, 211–219 [CrossRef Medline](#)
37. Penno, A., Reilly, M. M., Houlden, H., Laurá, M., Rentsch, K., Niederkofler, V., Stoeckli, E. T., Nicholson, G., Eichler, F., Brown, R. H., Jr., von Eckardstein, A., and Hornemann, T. (2010) Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. *J. Biol. Chem.* **285**, 11178–11187 [CrossRef Medline](#)
38. Gantner, M. L., Eade, K., Wallace, M., Handzlik, M. K., Fallon, R., Trombley, J., Bonelli, R., Giles, S., Harkins-Perry, S., Heeren, T. F. C., Sauer, L., Ideguchi, Y., Baldini, M., Scheppke, L., Dorrell, M. I., *et al.* (2019) Serine and lipid metabolism in macular disease and peripheral neuropathy. *N. Engl. J. Med.* **381**, 1422–1433 [CrossRef Medline](#)
39. Hannich, J. T., Haribowo, A. G., Gentina, S., *et al.* (2019) 1-Deoxydihydroceramide causes anoxic death by impairing chaperonin-mediated protein folding. *Nat. Metab.* **1**, 996–1008 [CrossRef](#)
40. Firmann, M., Mayor, V., Vidal, P. M., Bochud, M., Pécoud, A., Hayoz, D., Paccaud, F., Preisig, M., Song, K. S., Yuan, X., Danoff, T. M., Stirnadel, H. A., Waterworth, D., Mooser, V., Waeber, G., and Vollenweider, P. (2008) The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. *BMC Cardiovasc. Disord.* **8**, 6 [CrossRef Medline](#)
41. Kutalik, Z., Johnson, T., Bochud, M., Mooser, V., Vollenweider, P., Waeber, G., Waterworth, D., Beckmann, J. S., and Bergmann, S. (2011) Methods for testing association between uncertain genotypes and quantitative traits. *Biostatistics* **12**, 1–17 [CrossRef Medline](#)
42. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A., Bender, D., Maller, J., Sklar, P., de Bakker, P. I., Daly, M. J., and Sham, P. C. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* **81**, 559–575 [CrossRef Medline](#)
43. Marchini, J., Howie, B., Myers, S., McVean, G., and Donnelly, P. (2007) A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat. Genet.* **39**, 906–913 [CrossRef Medline](#)
44. Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J. Y., White, D. J., Hartenstein, V., Eliceiri, K., Tomancak, P., and Cardona, A. (2012) Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **9**, 676–682 [CrossRef Medline](#)
45. Storti, F., Klee, K., Todorova, V., Steiner, R., Othman, A., van der Velde-Visser, S., Samardzija, M., Meneau, I., Barben, M., Karademir, D., Pauzulyte, V., Boye, S. L., Blaser, F., Ullmer, C., Dunaief, J. L., Hornemann, T., Rohrer, L., den Hollander, A., von Eckardstein, A., Fingerle, J., Maugeais, C., and Grimm, C. (2019) Impaired ABCA1/ABCG1-mediated lipid efflux in the mouse retinal pigment epithelium (RPE) leads to retinal degeneration. *Elife* **8**, e45100 [CrossRef Medline](#)